UroGen Pharma downgraded by H.C. Wainwright
$URGN
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded UroGen Pharma from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $50.00 | Neutral → Buy | H.C. Wainwright |
| 5/22/2025 | Buy → Neutral | H.C. Wainwright | |
| 4/16/2025 | $23.00 | Sector Outperform | Scotiabank |
| 2/19/2025 | $31.00 | Buy | Ladenburg Thalmann |
| 8/22/2024 | $40.00 | Buy | Guggenheim |
| 2/8/2023 | $35.00 → $10.00 | Buy → Hold | Jefferies |
| 4/27/2022 | $20.00 | Buy | Berenberg |
| 1/18/2022 | $50.00 → $34.00 | Buy | HC Wainwright & Co. |
ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders maintained complete response at 12 months after the 3-month visit (DOR). Manageable safety profile characterized primarily by mild to moderate lower urinary tract symptoms. An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech com
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 27 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the continued development of the Company's pipeline. Up to 118,000 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares ve
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the presentation of the uTRACT Registry study design at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The uTRACT Registry is a single-arm, multicenter, prospective and retrospective study evaluating the real-world use of JELMYTO® (mitomycin) for pyelocalyceal solution for the treatment of adult patients with low-grade upper tract urothelial carcinoma (LG-UTUC) across the United States. "By capturing these real-world insights, the uTRACT Registry will inform best practices in the